The study was undertaken to examine the potential cross talk between vasopressin and angiotensin II (ANG II) intracellular signaling pathways. We investigated in vivo and in vitro whether vasopressin-induced water reabsorption could be attenuated by ANG II AT1 receptor blockade (losartan). On a low-sodium diet (0.5 meq/day) dDAVP-treated animals with or without losartan exhibited comparable renal function [creatinine clearance 1.2 Ϯ 0.1 in dDAVPϩlosartan (LSDL) vs. 1.1 Ϯ 0.1 ml·100 g Ϫ1 ·day Ϫ1 in dDAVP alone (LSD), P Ͼ 0.05] and renal blood flow (6.3 Ϯ 0.5 in LSDL vs. 6.8 Ϯ 0.5 ml/min in LSD, P Ͼ 0.05). The urine output, however, was significantly increased in LSDL (2.5 Ϯ 0.2 vs. 1.8 Ϯ 0.2 ml·100 g Ϫ1 ·day Ϫ1 , P Ͻ 0.05) in association with decreased urine osmolality (2,600 Ϯ 83 vs. 3,256 Ϯ 110 mosmol/kgH 2O, P Ͻ 0.001) compared with rats in LSD. Immunoblotting revealed significantly decreased expression of medullary AQP2 (146 Ϯ 6 vs. 176 Ϯ 10% in LSD, P Ͻ 0.01), p-AQP2 (177 Ϯ 13 vs. 214 Ϯ 12% in LSD, P Ͻ 0.05), and AQP3 (134 Ϯ 14 vs. 177 Ϯ 11% in LSD, P Ͻ 0.05) in LSDL compared with LSD. The expressions of AQP1, the ␣ 1-and ␥-subunits of Na-K-ATPase, and the Na-K-2Cl cotransporter were not different among groups. In vitro studies showed that ANG II or dDAVP treatment was associated with increased AQP2 expression and cAMP levels, which were potentiated by cotreatment with ANG II and dDAVP and were inhibited by AT1 blockade. In conclusion, ANG II AT1 receptor blockade in dDAVPtreated rats on a low-salt diet was associated with decreased urine concentration and decreased inner medullary AQP2, p-AQP2, and AQP3 expression, suggesting that AT1 receptor activation plays a significant role in regulating aquaporin expression and modulating urine concentration in vivo. Studies in collecting duct cells were confirmatory.aquaporin; urine concentration; cAMP THERE IS SUBSTANTIAL EVIDENCE that arterial underfilling, either due to decreased cardiac output, e.g., heart failure, or systemic arterial vasodilation, e.g., cirrhosis, is associated with activation of the neurohumoral axis, including the sympathetic nervous system, the renin-angiotensin system, and arginine vasopressin (AVP) (22,23). This neurohumoral response involves compensatory systemic vasoconstriction and renal sodium and water retention to attenuate the arterial underfilling.Much is known about the systemic effects of these components of neurohormonal activation by the use of angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid antagonists, and most recently vasopressin receptor antagonists (22,24,25). However, little is known about any potential interaction or cross talk between AVP and angiotensin II (ANG II) at the cellular and molecular level in the kidney.In the collecting duct, AVP binds to the vasopressin V2 receptor on the basolateral membrane of the principal cells, increasing the intracellular levels of cAMP via adenylyl cyclase and thereby activating protein kinase A, which phosphorylates aquaporin-2 (AQP2) with...